Moderna IncChange company Symbol lookupSelect an option...MRNA Moderna IncLVS Las Vegas Sands CorpPG Procter & Gamble CoAMP Ameriprise Financial IncSPHD Invesco S&P 500® High Dividend Low Volatility ETFMRK Merck & Co IncHD Home Depot IncSQM Sociedad Quimica y Minera de Chile SAAVGO Broadcom IncO Realty Income CorpGo
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
LVS Las Vegas Sands Corp
PG Procter & Gamble Co
AMP Ameriprise Financial Inc
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
MRK Merck & Co Inc
HD Home Depot Inc
SQM Sociedad Quimica y Minera de Chile SA
AVGO Broadcom Inc
O Realty Income Corp
Health Care : Biotechnology | Mid Cap Blend
Company profileModerna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.
|
|
|
|
| |
Latest Earnings (Q3 ending 09/2020)
- Q3 Non-GAAP earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
- -$0.59
- Q3 Consensus estimate
- -$0.43
Latest Earnings Estimate Range
- Highest
estimate - -$0.23
- Mean
estimate - -$0.43
- Lowest
estimate - -$0.95
Quarterly Consensus Estimates and Ranges
MRNA's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2020. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.